Cytomed Therapeutics six-month loss narrows to S$1.79 million; revenue rises to S$157,289
GDTC•Cytomed Therapeutics’ loss for the six months ended June 30, 2026, narrowed to S$1.79 million from S$2.25 million, while revenue rose to S$157,289 from S$155,887.
1. Six-month results
Loss per share improved to S$0.15 from S$0.19. Cash and bank balances fell to S$1.46 million at June 30, 2026, from S$2.10 million at Dec. 31, 2025, and net cash used in operating activities was S$1.65 million, compared with S$1.60 million a year earlier.
